{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:51:55Z","timestamp":1781589115887,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,15]]},"DOI":"10.7759\/cureus.110934","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:57:03Z","timestamp":1781585823000},"source":"Crossref","is-referenced-by-count":0,"title":["Prostate Cancer Screening: Current Controversies and Future Directions"],"prefix":"10.7759","author":[{"given":"Hasan F","family":"Buali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Al Shaibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar S","family":"Farouqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Abushloa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Bastawisy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noora","family":"Aljeeran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalifa","family":"Albenjasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Rafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James ND","year":"2024","unstructured":"James ND, Tannock I, N'Dow J, et al.. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024, 403:1683-722. 10.1016\/S0140-6736(24)00651-2","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.12.022","article-title":"Prostate-specific antigen in clinical practice","volume":"249","author":"Loeb S","year":"2007","unstructured":"Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett. 2007, 249:30-9. 10.1016\/j.canlet.2006.12.022","journal-title":"Cancer Lett"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104253241702","article-title":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","volume":"324","author":"Catalona WJ","year":"1991","unstructured":"Catalona WJ, Smith DS, Ratliff TL, et al.. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991, 324:1156-61. 10.1056\/NEJM199104253241702","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1320681","article-title":"Application and optimization of prostate-specific antigen screening strategy in the diagnosis of prostate cancer: a systematic review","volume":"13","author":"Zhang Z","year":"2023","unstructured":"Zhang Z, Tian A, Che J, Miao Y, Liu Y, Liu Y, Xu Y. Application and optimization of prostate-specific antigen screening strategy in the diagnosis of prostate cancer: a systematic review. Front Oncol. 2023, 13:1320681. 10.3389\/fonc.2023.1320681","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198710083171501","article-title":"Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate","volume":"317","author":"Stamey TA","year":"1987","unstructured":"Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987, 317:909-16. 10.1056\/NEJM198710083171501","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2586","article-title":"Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials","volume":"167","author":"Tsodikov A","year":"2017","unstructured":"Tsodikov A, Gulati R, Heijnsdijk EA, et al.. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017, 167:449-55. 10.7326\/M16-2586","journal-title":"Ann Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schr\u00f6der FH","year":"2014","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, et al.. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014, 384:2027-35. 10.1016\/S0140-6736(14)60525-0","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up","volume":"104","author":"Andriole GL","year":"2012","unstructured":"Andriole GL, Crawford ED, Grubb RL 3rd, et al.. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012, 104:125-32. 10.1093\/jnci\/djr500","journal-title":"J Natl Cancer Inst"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement","volume":"319","author":"Grossman DC","year":"2018","unstructured":"Grossman DC, Curry SJ, Owens DK, et al.. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018, 319:1901-13. 10.1001\/jama.2018.3710","journal-title":"JAMA"},{"key":"ref11","unstructured":"EAU Guidelines. Prostate Cancer. (2024). Accessed. March 1, 2026: https:\/\/uroweb.org\/guidelines\/prostate-cancer."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003491","article-title":"Early detection of prostate cancer: AUA\/SUO Guideline Part I: Prostate Cancer Screening","volume":"210","author":"Wei JT","year":"2023","unstructured":"Wei JT, Barocas D, Carlsson S, et al.. Early detection of prostate cancer: AUA\/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023, 210:46-53. 10.1097\/JU.0000000000003491","journal-title":"J Urol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1670671","article-title":"Utilization of artificial intelligence in prostate cancer detection: a comprehensive review of innovations in screening and diagnosis","volume":"16","author":"Rajih E","year":"2025","unstructured":"Rajih E, Bakhsh A, Borhan WM, Alqahtani SA. Utilization of artificial intelligence in prostate cancer detection: a comprehensive review of innovations in screening and diagnosis. Front Immunol. 2025, 16:1670671. 10.3389\/fimmu.2025.1670671","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101506","article-title":"Harnessing artificial intelligence for prostate cancer management","volume":"5","author":"Zhu L","year":"2024","unstructured":"Zhu L, Pan J, Mou W, et al.. Harnessing artificial intelligence for prostate cancer management. Cell Rep Med. 2024, 5:101506. 10.1016\/j.xcrm.2024.101506","journal-title":"Cell Rep Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.10.100","article-title":"Purification of a human prostate specific antigen","volume":"197","author":"Wang MC","year":"2017","unstructured":"Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. J Urol. 2017, 197:S148-52. 10.1016\/j.juro.2016.10.100","journal-title":"J Urol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp001","article-title":"Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context","volume":"101","author":"Draisma G","year":"2009","unstructured":"Draisma G, Etzioni R, Tsodikov A, et al.. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009, 101:374-83. 10.1093\/jnci\/djp001","journal-title":"J Natl Cancer Inst"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-017-0024-7","article-title":"Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer","volume":"21","author":"Nordstr\u00f6m T","year":"2018","unstructured":"Nordstr\u00f6m T, Akre O, Aly M, Gr\u00f6nberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis. 2018, 21:57-63. 10.1038\/s41391-017-0024-7","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3712","article-title":"Prostate-specific Antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force","volume":"319","author":"Fenton JJ","year":"2018","unstructured":"Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific Antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018, 319:1914-31. 10.1001\/jama.2018.3712","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed HU","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, et al.. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017, 389:815-22. 10.1016\/S0140-6736(16)32401-1","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan V","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, et al.. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018, 378:1767-77. 10.1056\/NEJMoa1801993","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2024.1429831","article-title":"Advances in multiparametric magnetic resonance imaging combined with biomarkers for the diagnosis of high-grade prostate cancer","volume":"11","author":"Li SL","year":"2024","unstructured":"Li SL, Zha MY, Wang Q, Tang Y. Advances in multiparametric magnetic resonance imaging combined with biomarkers for the diagnosis of high-grade prostate cancer. Front Surg. 2024, 11:1429831. 10.3389\/fsurg.2024.1429831","journal-title":"Front Surg"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.021","article-title":"A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer","volume":"68","author":"Parekh DJ","year":"2015","unstructured":"Parekh DJ, Punnen S, Sjoberg DD, et al.. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015, 68:464-70. 10.1016\/j.eururo.2014.10.021","journal-title":"Eur Urol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14385","article-title":"Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion","volume":"28","author":"Falagario UG","year":"2021","unstructured":"Falagario UG, Lantz A, Jambor I, et al.. Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion. Int J Urol. 2021, 28:47-52. 10.1111\/iju.14385","journal-title":"Int J Urol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31070272","article-title":"Quantifying the dosimetric impact of proton range uncertainties on RBE-weighted dose distributions in intensity-modulated proton therapy for bilateral head and neck cancer","volume":"31","author":"Rana S","year":"2024","unstructured":"Rana S, Manthala Padannayil N, Tran L, Rosenfeld AB, Saeed H, Kasper M. Quantifying the dosimetric impact of proton range uncertainties on RBE-weighted dose distributions in intensity-modulated proton therapy for bilateral head and neck cancer. Curr Oncol. 2024, 31:3690-7. 10.3390\/curroncol31070272","journal-title":"Curr Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan JL","year":"2016","unstructured":"Donovan JL, Hamdy FC, Lane JA, et al.. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016, 375:1425-37. 10.1056\/NEJMoa1606221","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy FC","year":"2016","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al.. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016, 375:1415-24. 10.1056\/NEJMoa1606220","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy FC","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al.. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023, 388:1547-58. 10.1056\/NEJMoa2214122","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer VA","year":"2012","unstructured":"Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012, 157:120-34. 10.7326\/0003-4819-157-2-201207170-00459","journal-title":"Ann Intern Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1139","article-title":"Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population","volume":"8","author":"Arroll B","year":"2010","unstructured":"Arroll B, Goodyear-Smith F, Crengle S, et al.. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Ann Fam Med. 2010, 8:348-53. 10.1370\/afm.1139","journal-title":"Ann Fam Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00497-7","article-title":"Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score","volume":"25","author":"Huynh-Le MP","year":"2022","unstructured":"Huynh-Le MP, Karunamuni R, Fan CC, et al.. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer Prostatic Dis. 2022, 25:755-61. 10.1038\/s41391-022-00497-7","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00361-7","article-title":"Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study","volume":"16","author":"Gr\u00f6nberg H","year":"2015","unstructured":"Gr\u00f6nberg H, Adolfsson J, Aly M, et al.. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 2015, 16:1667-76. 10.1016\/S1470-2045(15)00361-7","journal-title":"Lancet Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in Nordic countries","volume":"315","author":"Mucci LA","year":"2016","unstructured":"Mucci LA, Hjelmborg JB, Harris JR, et al.. Familial risk and heritability of cancer among twins in Nordic countries. JAMA. 2016, 315:68-76. 10.1001\/jama.2015.17703","journal-title":"JAMA"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.11.011","article-title":"Clinical implications of germline testing in newly diagnosed prostate cancer","volume":"4","author":"Loeb S","year":"2021","unstructured":"Loeb S, Giri VN. Clinical implications of germline testing in newly diagnosed prostate cancer. Eur Urol Oncol. 2021, 4:1-9. 10.1016\/j.euo.2020.11.011","journal-title":"Eur Urol Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407934","article-title":"Assessment of a polygenic risk score in screening for prostate cancer","volume":"392","author":"McHugh JK","year":"2025","unstructured":"McHugh JK, Bancroft EK, Saunders E, et al.. Assessment of a polygenic risk score in screening for prostate cancer. N Engl J Med. 2025, 392:1406-17. 10.1056\/NEJMoa2407934","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/503375-prostate-cancer-screening-current-controversies-and-future-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:57:17Z","timestamp":1781585837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/503375-prostate-cancer-screening-current-controversies-and-future-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.110934","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,15]]}}}